吴少华, 王华庆, 钱正子, 张会来, 周世勇, 邱立华, 宋拯, 王先火. 吉西他滨长春瑞滨联合吡喃阿霉素方案治疗复发难治T细胞淋巴瘤疗效分析[J]. 中国肿瘤临床, 2014, 41(10): 647-650. DOI: 10.3969/j.issn.1000-8179.20140559
引用本文: 吴少华, 王华庆, 钱正子, 张会来, 周世勇, 邱立华, 宋拯, 王先火. 吉西他滨长春瑞滨联合吡喃阿霉素方案治疗复发难治T细胞淋巴瘤疗效分析[J]. 中国肿瘤临床, 2014, 41(10): 647-650. DOI: 10.3969/j.issn.1000-8179.20140559
shu
WU Shaohua, WANG Huaqing, QIAN Zhengzi, ZHANG Huilai, ZHOU Shiyong, QIU Lihua, SONG Zheng, WANG Xianhuo. Gemcitabine, navelbine, and therarubicin (GNT) as treatment for patients with refractory or relapsed T-cell lymphoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 41(10): 647-650. DOI: 10.3969/j.issn.1000-8179.20140559
Citation: WU Shaohua, WANG Huaqing, QIAN Zhengzi, ZHANG Huilai, ZHOU Shiyong, QIU Lihua, SONG Zheng, WANG Xianhuo. Gemcitabine, navelbine, and therarubicin (GNT) as treatment for patients with refractory or relapsed T-cell lymphoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 41(10): 647-650. DOI: 10.3969/j.issn.1000-8179.20140559
shu

吉西他滨长春瑞滨联合吡喃阿霉素方案治疗复发难治T细胞淋巴瘤疗效分析

Gemcitabine, navelbine, and therarubicin (GNT) as treatment for patients with refractory or relapsed T-cell lymphoma

    摘要
  • 摘要:
      目的   探讨吉西他滨、长春瑞滨联合吡喃阿霉素（GNT）方案对复发难治T细胞淋巴瘤（TCL）患者的疗效和毒副作用。
      方法   应用GNT方案治疗69例复发难治TCL患者，方案为吉西他滨800 mg/m2，d1、8，长春瑞滨25 mg/m2，d1，吡喃阿霉素20 mg/m2，d1，21天为1个周期。
      结果   总有效率（ORR）为65.2%，其中CR为29.0%。主要不良反应为血液学毒性。患者1、3、5年OS分别是71.7%、47.3%、32.4%，中位生存期为36个月。
      结论   GNT方案治疗复发难治TCL疗效较高、可耐受。

     

    Abstract:
      Objective   This study was conducted to evaluate and discuss the curative effect and toxicity of gemcitabine, navel-bine, and therarubicin (GNT) regimen for patients with refractory or relapsed T-cell lymphoma (TCL).
      Methods   A total of 69 patients with refractory or relapsed TCL treated with GNT were enrolled. The treatment protocol was set as follows: 800 mg/m2 gemcitabine ad-ministered at 1 and 8 d; 25 mg/m2 navelbine administered at 1 d; and 20 mg/m2 therarubicin administered at 1 d. This protocol was re-peated every three weeks. The median cycle was 4 (range: 2 to 6).
      Results   The overall response rate was 65.2% and the achieved com-plete remission was 29.0%. Hematology toxicities were the main adverse reactions observed in all of the patients. The incidence rates of grades 1 and 2 toxicity in leukopenia or neutropenia, anemia, and thrombocytopenia were 50.7%, 33.3%, and 26.1%, respectively. Grades 3 and 4 treatment-associated toxicities were detected in 23.1% of the responding patients. One-, three-, and five-year estimated overall survival (OS) of the whole cohort were 71.7%, 47.3%, and 32.4%, respectively. The median OS was 36 months.
      Conclusions   GNT was effective and suitable for patients with refractory or relapsed TCL.

     

    • HTML全文
    • 参考文献(17)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回